Compare JetBlue Airways Corporation (JBLU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? JetBlue Airways Corporation trades at $5.81 (market cap $2.13B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 62.3× JetBlue Airways Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| JBLU | VRTX | |
|---|---|---|
Market Cap | $2.13B | $132.79B |
Sector | Industrials | Health |
52-Week High | $6.46 | $529.65 |
52-Week Low | $4.03 | $376.62 |
Enterprise Value | $9.49B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $6.07, down 1.94% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a Q2 2026 earnings beat but continues to post net losses, with negative profit margins and declining revenue trends. Recent news includes analyst downgrades from Citigroup citing geopolitical risks, though the company has introduced new fare structures and lounge enhancements to drive growth.
The outlook remains challenging with persistent losses and high debt levels, though cost management and strategic initiatives offer potential upside. Key risks include fuel cost volatility, competitive pressures, and execution of the 2028 profit target. Analyst consensus is cautious with a $5.18 price target below current levels, reflecting skepticism about near-term profitability.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
